Glucosamine: The Amino Sugar Your Body Makes From Glucose

Glucosamine is one of the best-selling joint supplements, yet every cell in your body already makes it from three things it always has on hand: glucose, glutamine and ATP. This page starts there, with how the body builds it, and then follows the evidence. The large independent trials found little or no benefit for joint pain over placebo, and major arthritis guidelines now recommend against it. The pathway glucosamine feeds is also one of the cell's sensors for too much sugar. Taken together, the research does not support glucosamine supplements for joint pain, and the blood-sugar findings raise a particular question for people with diabetes, prediabetes, high blood sugar or a raised HbA1c.

Table of Contents

  1. Deep-Dive Articles
  2. Glucosamine at a Glance
  3. How the Body Makes Glucosamine
  4. What Glucosamine Does in the Body
  5. The Supplement Claim: Joint Pain
  6. Blood Sugar: What the Research Shows for People With Diabetes
  7. What About Glutamine Instead?
  8. Other Safety Concerns
  9. The Evidence in Summary
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Deep-Dive Articles

🧪

How the Body Makes Glucosamine

Glucose, glutamine and ATP, three enzyme steps, and the GFAT gatekeeper, drawn step by step in two diagrams.

Read the deep dive →
🩸

Glucosamine, Blood Sugar and Diabetes

The sugar-sensing pathway, the human studies that point both ways, and what they mean for people with high blood sugar.

Read the deep dive →
⚖️

Glutamine Instead of Glucosamine?

Would glutamine let the body spend its extra glucose making its own? What the glutamine trials actually found, and why.

Read the deep dive →
🦴

Glucosamine for Joint Pain: What the Trials Found

From the hopeful early trials to GAIT, LEGS, the meta-analyses and today's guidelines.

Read the deep dive →
⚠️

Glucosamine Safety

Blood sugar, warfarin and bleeding, eye pressure, shellfish and kidneys: who the research raises concerns for, and why.

Read the deep dive →
🧠

Glucosamine and Alzheimer's Disease

The 2026 study linking glucosamine to faster decline, the re-check that found the same signal for multivitamins, and what it means.

Read the deep dive →
📜

History of Glucosamine

From an 1876 experiment on lobster shell to a supplement boom and the trials that tested it.

Read the deep dive →

Back to Table of Contents

Glucosamine at a Glance

QuestionShort answer
What is it?An amino sugar: glucose with a nitrogen group in place of the hydroxyl group on carbon 2.
Does the body make it?Yes, in every cell, from glucose + glutamine + ATP (the hexosamine pathway).
What is it used for?Building joint fluid (hyaluronan), cartilage, mucus and the sugar chains on proteins, and as a nutrient signal inside cells.
Do supplements help joint pain?Large independent trials found little or no benefit over placebo; ACR 2019 and OARSI 2019 recommend against.
Who does the research raise concerns for?People with diabetes, prediabetes, high fasting glucose or a raised HbA1c; people with memory problems, mild cognitive impairment or Alzheimer's disease; people on warfarin; people with glaucoma.
What the evidence showsThe body makes its own, and a benefit from supplements has not been shown in large independent trials.

Back to Table of Contents

How the Body Makes Glucosamine

Glucosamine is made inside the cell, in the cytoplasm, by the first part of the hexosamine biosynthesis pathway, a side road off glycolysis. It takes three ingredients:

IngredientWhat it isRole in the process
GlucoseA six-carbon sugar from food, carried in the bloodSupplies the carbon skeleton of glucosamine
ATPThe cell's energy-carrying moleculeDonates one phosphate group in Step 1 and becomes ADP
GlutamineAn amino acidDonates the nitrogen (amino group) in Step 3 and becomes glutamate
  1. Step 1. Hexokinase, with magnesium, uses ATP to turn glucose into glucose-6-phosphate, trapping it in the cell.
  2. Step 2. Phosphoglucose isomerase rearranges it into fructose-6-phosphate. About 97% of this goes on to be burned in glycolysis; about 3% branches off (Buse 2006).
  3. Step 3. GFAT moves the nitrogen from glutamine onto the sugar, giving glucosamine-6-phosphate and glutamate. This is the rate-limiting step, and the pathway's end product, UDP-GlcNAc, feeds back to slow it (Ruegenberg 2020).

Glucose + ATP + Glutamine → Glucosamine-6-phosphate + ADP + Glutamate

A three-column diagram of how the body makes glucosamine: glucose, ATP and glutamine enter on the left; down the middle, hexokinase, an isomerase and GFAT turn glucose into glucose-6-phosphate, fructose-6-phosphate and finally glucosamine-6-phosphate, while ADP and glutamate leave and about 97% of the sugar branches off to glycolysis; colour tracks the carbon skeleton from glucose, the phosphate from ATP and the nitrogen from glutamine. HOW THE BODY MAKES GLUCOSAMINE three ingredients · three enzyme steps · inside every cell THE INGREDIENTS THE SYNTHESIS WHERE EACH PART GOES Glucose the six-carbon skeleton ATP one phosphate tag none of the three comes from a bottle: blood sugar, the cell's energy carrier and the body's own glutamine Glutamine its nitrogen glucose enters the cell from the blood STEP 1 · hexokinase · magnesium ADP leaves glucose-6-phosphate the phosphate traps it inside STEP 2 · isomerase · same atoms, new ring fructose-6-phosphate the fork in the road about 97% to glycolysis, energy STEP 3 · GFAT · about 3% of the sugar glutamate leaves glucosamine-6-phosphate glucose + phosphate + nitrogen the carbon skeleton all six carbons were blood glucose the phosphate tag from ATP, which becomes ADP; it keeps the sugar in the cell the nitrogen from glutamine, which becomes glutamate; it replaces the -OH group on carbon 2 glucose + ATP + glutamine → glucosamine-6-phosphate + ADP + glutamate GFAT sets the pace, and the pathway's end product slows it
Follow the colours: the violet ring is the carbon skeleton from glucose, the cyan dot is the phosphate from ATP, and the green dot is the nitrogen from glutamine. All three end up in glucosamine-6-phosphate at the bottom of the middle column. The thick arrow is Step 3, run by GFAT, the enzyme that sets how much glucosamine the cell makes; most of the sugar never reaches it and goes to glycolysis instead.

The full walk-through, with a second diagram of the feedback brake and of where supplement glucosamine enters, is on How the Body Makes Glucosamine.

Back to Table of Contents

What Glucosamine Does in the Body

Glucosamine-6-phosphate is quickly finished into UDP-GlcNAc, the "activated" amino sugar the body builds with (Buse 2006). It ends up in:

That last role is why glucosamine matters for blood sugar: the pathway reports to the cell how much sugar is coming in.

Back to Table of Contents

The Supplement Claim: Joint Pain

The idea behind the supplement is simple: cartilage is built from amino sugars, so swallowing one was expected to help rebuild worn cartilage. Early trials of one pharmaceutical form looked encouraging (Reginster 2001). But after a 1,500 mg dose, blood levels reach only about 2 to 12 micromoles per litre (Biggee 2006), and the large independent trials told a different story:

Details, including the trials that were positive, are on Glucosamine for Joint Pain: What the Trials Found.

Back to Table of Contents

Blood Sugar: What the Research Shows for People With Diabetes

In 1991 Marshall's group found that the hexosamine pathway is how fat cells sense excess glucose and become insulin resistant, and that glucosamine, which enters past the GFAT gatekeeper, was "at least 40 times more potent than glucose" at causing it in cells (Marshall 1991). Human results are mixed:

Put together, the research shows no proven benefit and a plausible risk, and that risk concerns people with diabetes, prediabetes, high fasting glucose or a raised HbA1c most. Fasting glucose and HbA1c are the measurements these studies used, and questions about any supplement are for a clinician. Full detail: Glucosamine, Blood Sugar and Diabetes.

Back to Table of Contents

What About Glutamine Instead?

If the body makes glucosamine from glucose and glutamine, would it be better to take glutamine and let the body use up some of its extra glucose making its own? The research gives a split answer:

The doses studied were large, the trials small and short, and glutamine is not a diabetes treatment. The full comparison is on Glutamine Instead of Glucosamine?

Back to Table of Contents

Other Safety Concerns

Full detail: Glucosamine Safety.

Back to Table of Contents

The Evidence in Summary

Back to Table of Contents

Key Research Papers

  1. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. Journal of Biological Chemistry. 1991;266(8):4706-4712. — PubMed PMID: 2002019
  2. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. American Journal of Physiology-Endocrinology and Metabolism. 2006;290(1):E1-E8. — doi:10.1152/ajpendo.00329.2005 (PubMed PMID: 16339923)
  3. Ruegenberg S, Horn M, Pichlo C, et al. Loss of GFAT-1 feedback regulation activates the hexosamine pathway that modulates protein homeostasis. Nature Communications. 2020;11(1):687. — doi:10.1038/s41467-020-14524-5 (PubMed PMID: 32019926)
  4. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017-1022. — doi:10.1038/nature05815 (PubMed PMID: 17460662)
  5. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Annals of the Rheumatic Diseases. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)
  6. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256. — doi:10.1016/S0140-6736(00)03610-2 (PubMed PMID: 11214126)
  7. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795-808. — doi:10.1056/NEJMoa052771 (PubMed PMID: 16495392)
  8. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. — doi:10.1136/bmj.c4675 (PubMed PMID: 20847017)
  9. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology. 2020;72(2):220-233. — doi:10.1002/art.41142 (PubMed PMID: 31908163)
  10. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578-1589. — doi:10.1016/j.joca.2019.06.011 (PubMed PMID: 31278997)
  11. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes. 2000;49(6):926-935. — doi:10.2337/diabetes.49.6.926 (PubMed PMID: 10866044)
  12. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. American Journal of the Medical Sciences. 2007;333(6):333-339. — doi:10.1097/MAJ.0b013e318065bdbe (PubMed PMID: 17570985)
  13. Biggee BA, Blinn CM, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Annals of the Rheumatic Diseases. 2007;66(2):260-262. — doi:10.1136/ard.2006.058222 (PubMed PMID: 16818461)
  14. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006;55(11):3142-3150. — doi:10.2337/db06-0714 (PubMed PMID: 17065354)
  15. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Archives of Internal Medicine. 2003;163(13):1587-1590. — doi:10.1001/archinte.163.13.1587 (PubMed PMID: 12860582)
  16. Gommans YMM, Runhaar J, Jacobs ML, et al. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. American Journal of Medicine. 2017;130(6):731-737.e6. — doi:10.1016/j.amjmed.2016.11.038 (PubMed PMID: 28011309)
  17. Ma H, Li X, Zhou T, et al. Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank. Diabetes Care. 2020;43(4):719-725. — doi:10.2337/dc19-1836 (PubMed PMID: 31988063)
  18. Riahi Y, Kogot-Levin A, Teselpapa Z, et al. Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes. JCI Insight. 2026;11(10):e197331. — doi:10.1172/jci.insight.197331 (PubMed PMID: 42171606)
  19. Greenfield JR, Farooqi IS, Keogh JM, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. American Journal of Clinical Nutrition. 2009;89(1):106-113. — doi:10.3945/ajcn.2008.26362 (PubMed PMID: 19056578)
  20. Samocha-Bonet D, Wong O, Synnott EL, et al. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. Journal of Nutrition. 2011;141(7):1233-1238. — doi:10.3945/jn.111.139824 (PubMed PMID: 21593352)
  21. Mansour A, Mohajeri-Tehrani MR, Qorbani M, et al. Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes. Nutrition. 2015;31(1):119-126. — doi:10.1016/j.nut.2014.05.014 (PubMed PMID: 25466655)
  22. Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy. 2008;28(4):540-548. — doi:10.1592/phco.28.4.540 (PubMed PMID: 18363538)
  23. Murphy RK, Ketzler L, Rice RD, et al. Oral glucosamine supplements as a possible ocular hypertensive agent. JAMA Ophthalmology. 2013;131(7):955-957. — doi:10.1001/jamaophthalmol.2013.227 (PubMed PMID: 23702812)
  24. Esfandiari H, Pakravan M, Zakeri Z, et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye. 2017;31(3):389-394. — doi:10.1038/eye.2016.221 (PubMed PMID: 27768119)
  25. Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? Journal of Allergy and Clinical Immunology. 2004;114(2):459-460. — doi:10.1016/j.jaci.2004.05.050 (PubMed PMID: 15341031)
  26. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026;8(6):1410-1425. — doi:10.1038/s42255-026-01538-4 (PubMed PMID: 42265388)
  27. Nakashima S, Sato K, Niimi Y, et al. Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer's disease. medRxiv [preprint]. 2026:2026.07.23.26358748. — doi:10.64898/2026.07.23.26358748 (PubMed PMID: 42619916)

PubMed Topic Searches

  1. PubMed: Glucosamine and insulin resistance
  2. PubMed: Glucosamine trials in knee osteoarthritis
  3. PubMed: The hexosamine biosynthesis pathway
  4. PubMed: Glutamine, GLP-1 and type 2 diabetes

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

Back to Table of Contents